USPTO serial 79363759
SYNTAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 11, 2025
- Examiner
- CORNWELL, ANDREA B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYNTAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bryce J. Maynard
Bryce J. Maynard Buchanan Ingersoll & Rooney PC1737 King Street, Suite 500Alexandria, VA 22314United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, reagents, enzymes, and kits comprising enzymes, nucleotide monomers, solid phase synthesis media, and synthesis plates for laboratory use, all for use in scientific research, namely, for use in synthesizing polynucleotides, namely, for amplifying, assembling and modifying genetic fragments, genotyping, gene modification, and analyzing biological systems, samples and cells, in the course of scientific research conducted in clinical, medical and biological facilities and laboratories using or storing nucleic acid molecules; stem cells other than for medical or veterinary use; chemical preparations for analyses in laboratories other than for medical or veterinary use; protein in raw material form for scientific research; all the aforesaid goods other than those directly for use in the cardiovascular field | ACTIVE | — |
| 005 | Chemical reagents and enzymes for medical use, namely, for use in synthesizing polynucleotides, namely, for amplifying, assembling, modifying genetic fragments, genotyping, gene modification, and analysis of biological systems, samples and cells, in clinical, medical and biological facilities and laboratories using or storing nucleic acid molecules; stem cells for medical use; stem cells for veterinary use; all the aforesaid goods other than those directly for use in the cardiovascular field | ACTIVE | — |
| 009 | Apparatus and instruments for laboratory and scientific use for polynucleotide synthesis in the field of DNA and RNA, namely, pipetors, liquid handlers, laboratory columns for chemical synthesis, scientific apparatus and instruments for measuring relative DNA, RNA and protein, laboratory research instruments for DNA analysis, as well as parts and accessories for such apparatus and instruments, namely, laboratory glassware in the nature of bottles, flasks, cartridges, vials, reaction plates, synthesis supports, and reaction tubes, as well as computer hardware and downloadable computer software relating thereto for use in operating and interfacing with apparatus and instruments for synthesizing polynucleotides; apparatus and instruments for laboratory and scientific use in using or storing nucleic acid molecules, particularly for amplification, assembly or modification of genetic fragments, genotyping, gene modification and analysis of biological cells, samples or systems, namely, laboratory devices for detecting genetic sequences, scientific apparatus and instruments for measuring relative DNA, RNA and protein, electrical equipment for the genetic modification of cells for research purposes, laboratory apparatus and instruments for extracting nucleic acid; DNA chips; Apparatus for scientific use for preservation, storage or processing of DNA chips containing information, namely, scientific apparatus and instruments for measuring relative DNA, RNA and protein, laboratory apparatus and instruments for extracting nucleic acid; computer hardware and recorded and downloadable computer software for use in apparatus and instruments for synthesizing polynucleotides; computer hardware and recorded and downloadable computer software for polynucleotide synthesis, namely, DNA and RNA; computer hardware and recorded and downloadable computer software for use in amplifying, assembling or modifying genetic fragments, genotyping, gene modification and analysis of biological cells, samples or systems; computer hardware and recorded and downloadable computer software for use in preserving, storing or processing DNA chips containing information; biochips for scientific research purposes and data storage purposes; all the aforesaid goods other than those directly for use in the cardiovascular field | ACTIVE | — |
| 010 | DNA and RNA testing apparatus for medical use; DNA sample testing apparatus for medical use; diagnostic apparatus for medical use for the detection of genetic particularities, mutations and diseases; analysis devices for identification of bacteria for medical use; all the aforesaid goods other than those directly for use in the cardiovascular field | ACTIVE | — |
| 042 | Technical research in the field of polynucleotide synthesis; biological research; chemical research; medical research; chemical analysis; chemistry services, namely, research and laboratory analysis in the field of chemistry; scientific laboratory services; designing and testing synthetic DNA for scientific research purposes; polynucleotide synthesis services, namely, DNA and RNA synthesis for scientific research purposes; computer services for storing nucleic acid molecules, particularly, cloud storage services for electronic data comprising visual representations of nucleic acid molecules for use in amplification, assembly or modification of genetic fragments, genotyping, gene modification and analysis of cells, samples or biological systems on DNA chips containing information; biological research laboratory services in the field of nucleic acid molecules, particularly for amplification, assembly or modification of genetic fragments, genotyping, gene modification and analysis of cells, samples or biological systems on DNA chips containing information; chemical laboratory services in the field of nucleic acid molecules, particularly for amplification, assembly or modification of genetic fragments, genotyping, gene modification and analysis of cells, samples or biological systems on DNA chips containing information; scientific research and laboratory services in the field of nucleic acid molecules, particularly for the amplification, assembly or modification of genetic fragments, genotyping, gene modification and analysis of cells, samples or biological systems on DNA chips containing information; computer services for the preservation, storage or processing of data on DNA chips containing information, namely, providing temporary use of online non-downloadable computer software for preserving, storing and processing data in the field of DNA; biological research laboratory services for preservation or processing of data on DNA chips containing information; chemical laboratory services for preservation or processing of data on DNA chips containing information; scientific research and laboratory services for the preservation or processing of data on DNA chips containing information; technical research in the field of DNA and RNA, namely, conducting of technical project studies; software development and design; software rental, namely, rental of computer software for operating apparatus and instruments for DNA and RNA synthesis; digitization of documents; Software as a Service (SaaS) featuring software for operating apparatus and instruments for DNA and RNA synthesis; cloud computing featuring software for operating apparatus and instruments for DNA and RNA synthesis; graphic arts design services; styling being industrial design services; authentication of works of art; energy auditing; all the aforesaid services other than those directly for use in the cardiovascular field | ACTIVE | — |
| 044 | Medical services; veterinary services; cosmetic and medical skin care services for beauty and sanitary care purposes; medical assistance; plastic surgery; hospital services; medical analysis services provided by medical laboratories for diagnostic and treatment purposes; advice with respect to health in the field of DNA and its preservation; consultation with respect to pharmaceuticals; all the aforesaid services other than those directly for use in the cardiovascular field | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DNA SCRIPT
- Other trademarks owned by DNA SCRIPT
- Other trademarks owned by DNA SCRIPT
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SYNTAX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 11, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 23, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 23, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 11, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 11, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 11, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 23, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 23, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 17, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 26, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 20, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 20, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 20, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 20, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 20, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 20, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 31, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 11, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 22, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 21, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 16, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 15, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 15, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 15, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 30, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 30, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 31, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 11, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 11, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 21, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 20, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 27, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |